N
Google TrendSOX SCORE (1000+) — MLB playoffs 2026: Inside White Sox's postseason pitching plan
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:sox score1000+bill maher500+ben simmons500+lisa200+sherrod brown1000+mn gophers2000+will venable1000+kalshi1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Outcomes of relapse after" (30 stories)

Top Headline Story

Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal
Lead StoryNaturegeneral
Nov 5, 2025

Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MTDR1TjRkM3JyUDdGd1FnOHRHcXFOU1Y5R2YxVHRXQndyVDIzdm9XZjZCUklvaGduTGRyVzlRN1dHS1h2Y0lYM1FWanlGam5fUDVkR25Ua3RwMy1nT0pv?oc=5" target="_blank">Outcomes of relapse after teclistamab therapy in multiple myeloma - Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+24m ago

sox score

MLB playoffs 2026: Inside White Sox's postseason pitching plan

Filter stories
500+24m ago

bill maher

Michael Douglas Tells Bill Maher About Smuggling Marijuana in Suitcases, Slams ‘Nepo Baby’ Label

Filter stories
500+24m ago

ben simmons

Ben Simmons to make his Kings debut against Golden State

Filter stories
200+24m ago

lisa

Trump Announces White House Inquiry Into Fed Governor Lisa Cook

Filter stories

Search Results for "Outcomes of relapse after"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Time-resolved predictability of end-of-therapy outcome and relapse after cure in Phase 3 tuberculosis trials
medRxivgeneral

Time-resolved predictability of end-of-therapy outcome and relapse after cure in Phase 3 tuberculosis trials

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE95dmdvZWdYaVpNMlVBTFhiRmxWTkoxeTVoNkQ4MzByQ290a0ZtS2t0aHFWbElKYUZqWUFQSzFWbzVzd3dGNlhyM2hwWTZVWFpIN3Z4WDhVdFhJLW9VYjNCR1pFYUR5dnAyWWdXLVZzeFkwY2Q5V1FZX3IyMmM?oc=5" target="_blank">Time-resolved predictability of end-of-therapy outcome and relapse after cure in Phase 3 tuberculosis trials</a>  <font color="#6f6f6f">medRxiv</font>

Read Full StoryMore like this
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma
University of Miamigeneral

Teclistamab Improves Outcomes in Relapsed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQXzd3YnBUSFpmbkZ0ZXBFdWZSdjRlUUtFclJkNG1zRHFuOXhzX1VLSGtNOWtoOWFWS0tOT2dnX3pVVm5RUU0yRUVkYzd0NnV1djRNSkYwNm4tVS1XTGxvNGNBUjJyUUdEZjNyWDQzdmpwSU1PQ09CbHp5c0lVWWNxV2F5VGx1SElsS1JUV3lmRQ?oc=5" target="_blank">Teclistamab Improves Outcomes in Relapsed Multiple Myeloma</a>  <font color="#6f6f6f">University of Miami</font>

Read Full StoryMore like this
Mayo Clinic study finds new post-liver transplant protocol results in 0% heavy alcohol relapse rate
Mayo Clinic News Networkgeneral

Mayo Clinic study finds new post-liver transplant protocol results in 0% heavy alcohol relapse rate

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPZ1lXTGlKOXNKZ2xmcnVqcWVlSFJKeDFyUzZSTzBxU3RyR2FMbHFEMHRaWGRvZzhqY1JrLXh2bWdYZTFSeVVRUWN0OXhfOG00T3VfWk5OZWtRdHVid2NMR3gxZ2I0dm82eFNnZ2hzbm9kejBncS03T0x0Tzk5UmppQ25ST2ZGdlFsazM3TmV4UnRsREY3VEs4MjYxMl9Xd1NnVlViOEdEdFdkcGF0UGluUmhnLTlFRTkweVlyZXVlejIyTTc4Y0JPVlFMaUUzTjlHdU85VkltZ0xBYnl0VUE?oc=5" target="_blank">Mayo Clinic study finds new post-liver transplant protocol results in 0% heavy alcohol relapse rate</a>  <font color="#6f6f6f">Mayo Clinic News Network</font>

Read Full StoryMore like this
Talquetamab-Based Combinations Improve Outcomes for Relapsed Multiple Myeloma
https://news.cancerconnect.com/general

Talquetamab-Based Combinations Improve Outcomes for Relapsed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPcHRZdnR1MzVwOUdGSEQ3akFxSTY0VTdJRlJSVkNiQkh4M25OU3lhOWhPbEFwbld3Q0toLTV6WW9sWVNTWWEzQ3VsdTBBRUJueWFqTTVUZWxHVVl3MFoxUWlEdUw0SE9XXy0teGJPUGVaeS13eGxTTU83UGhtQ3o2ejlBelFqQU9ocVFteWJVeGtLWGg2bUstWERoeWgyV2JrU0lSNWhjbkR4N0NIMWc?oc=5" target="_blank">Talquetamab-Based Combinations Improve Outcomes for Relapsed Multiple Myeloma</a>  <font color="#6f6f6f">https://news.cancerconnect.com/</font>

Read Full StoryMore like this
Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse
Wiley Online Librarygeneral

Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE5ieVpPLTY2dEFFZFItdjJuZS1jd2xmMzdUb0hBbEVrZVNwNFFHejRUTkxuekNmNGNNWENtekcwMHJtek9tTUNnT085a3l0RlNMblgtVmhFaG9BZFpYNUVJT1VZWGJ3THNkMVRF?oc=5" target="_blank">Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Predictors of Clinical Outcome in Primary Progressive and Relapsed Wilms Tumor in a Resource-Limited Setting
Cureusgeneral

Predictors of Clinical Outcome in Primary Progressive and Relapsed Wilms Tumor in a Resource-Limited Setting

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQUld2ckI2UGJZSGdwTS1xMTNMbWZ2TnNlaXB5Tzh1WWRyMl84YmNxUXJxbjNuUGttYV94ZGxUWmpZeFRzdFJoZnFYV3dkN2JfNmczM0dFNDE4cWRQTnBZdEUyTmNyc3g5TzgtaHJVczhBS3dueW9HcHk3OVlITG1DenA0V2xSWlY1RFlnalUtLTdZeEZmMldsbU5hMnUwUlZuYWJvS3E0V1FISVFrZm5kZnd4eW02ZXE2VGgzTzRiV0ZXM0lmOUlXOXh3ZFpIaEZhNnlBTDdScHptR3hTMDhhNw?oc=5" target="_blank">Predictors of Clinical Outcome in Primary Progressive and Relapsed Wilms Tumor in a Resource-Limited Setting</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Naturegeneral

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1XWkN5ZHVSQ3VWdFM4WGVnV29vdnJqc19oRE5hYmx0Vk44OXlwdzBsMEg5VVBxZlZKVTZnZEFoRlBRdmZDdkdXS2ppeE9rMTJHRWhMOEVxN0JnQTVna0lZ?oc=5" target="_blank">Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma
Medscapegeneral

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPaWVfWUp6LVprRHVFaXdocmYyR0otRE1UdG9zN1VPV0FkQVBnWVVxZm5jRndWWFN3Ymp0SkJhZWZMV0VOY0g2S2QyeXgzdW1QRWJUTndvSHhEdnZ0cHkyOURRc0d4WkxLRXQ0a1N1elNzOGZLRFNOUzYxU05oRzZpWnNwLU42aFo4S0JVYjF6dmFRc1VzWGFTOG1pNXBXZDlIeHgtMzBwTDhoRGs?oc=5" target="_blank">HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Outcomes and risk of relapse after living donor and deceased donor liver transplantation for alcohol-associated liver disease
www.elsevier.comgeneral

Outcomes and risk of relapse after living donor and deceased donor liver transplantation for alcohol-associated liver disease

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPVktvWFZjQTBxWk1uYTJ2NlA0dGcwSzY3Zzd1MHM1YWg3SEgwbHhEUldIUWtTMmZpOURDLTJuYVZyYUhXdjJMM2psTEY1MDJVZ0xRTVNrVGRQbWplQWRBekFlMy1XRDFaRG9fSWlMTS1NbHFwOExYX09nNGF0R1JaTWhMV2ZIWEY5eUdxNnZCLXk1QVRvSGQxSmx3TFlCUVV4dXFXQ00wckc0TmwtVjFxOXJHYjFKZEVo?oc=5" target="_blank">Outcomes and risk of relapse after living donor and deceased donor liver transplantation for alcohol-associated liver disease</a>  <font color="#6f6f6f">www.elsevier.com</font>

Read Full StoryMore like this
Mechanisms of relapse and post-relapse outcomes following FLT3 inhibitor therapy in FLT3-mutated AML
aml-hub.comgeneral

Mechanisms of relapse and post-relapse outcomes following FLT3 inhibitor therapy in FLT3-mutated AML

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNc25JdV9QME4tV0ZvLUJtU3VSbkdTeHhnUFhMb1hMVHVDaVpQcnhiYl9IMVYxVkVXaFc1aWFuTVhMQm1YTUlmcVlRWW5vNU0xaU5OVWs0V3NGek1HajRrRTNVX0ZpSzRraVoydDI2RFFORnNRc214b0dpc3J4TlNud3A5RGhVZEVkN29YT3pHU0o4bTlGeWZJMkRoZHgzWDg2Y2FEQldTZFQyTExrSjJKc19UV3Y1eDVoZlloV2hkYlFZdVBxbGY0dVVMZDlZNkVuUkUxbmgtRQ?oc=5" target="_blank">Mechanisms of relapse and post-relapse outcomes following FLT3 inhibitor therapy in FLT3-mutated AML</a>  <font color="#6f6f6f">aml-hub.com</font>

Read Full StoryMore like this
Real-World Outcomes With Bispecifics in Relapsed/Refractory Large B-Cell Lymphoma
MedPage Todayworld

Real-World Outcomes With Bispecifics in Relapsed/Refractory Large B-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1DUTlQWVlqX2l3RzZnZ2F2WDV1UU1rMEwzbk1JcEpEd0poRDhTbXRsLVhsMEo1elNKM1Z3eEpQV3Jya0tVRHJNVmJNNU5kUDN5V1Q3VlNlN0hiVDBKU1EwdnZDTm1KTlFrMWVpS3RvY0JDc3ZaQS1uUFdFYw?oc=5" target="_blank">Real-World Outcomes With Bispecifics in Relapsed/Refractory Large B-Cell Lymphoma</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Wiley Online Librarygeneral

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTFBrM3ZldDJBanIxVmFjOUhvZEhCZzVRX2s3aXNmNkdmN0p6U3NoX25pbDhPZEJuRWc2emxHVFBhWngtM0xsMm53em1XdS1EUU5pbXQ1YkdNYkljRTZGeVcyWkRIQlA2NnhKOXVZ?oc=5" target="_blank">Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
Haematologicageneral

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE1TNFpsbFhxWWtnMkRjWkpwbEtFcUFmeEFtc254bnJLaUl1OGxkT0M5V1dGNmREaGQ1VFRwdy1OZzJpTlNXS0s5TVlZTElvZVd3Um9qNlRtRQ?oc=5" target="_blank">Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma</a>  <font color="#6f6f6f">Haematologica</font>

Read Full StoryMore like this
Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy | Bone Marrow Transplantation
Natureworld

Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy | Bone Marrow Transplantation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1uV0hIRVllV01QR3BORE1vN2hiUjR6NWNRSGNHYTNyZXJXbGRXU0ZxZ1ZTUEdLZTVTcTVCSENTYTFhNktoamJxTFBaSnZIMndCS250a3ZSdllXQ2tlV0Nz?oc=5" target="_blank">Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy | Bone Marrow Transplantation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Outcomes in Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Curative-Intent Treatment
The ASCO Postworld

Outcomes in Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Curative-Intent Treatment

<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxQVlUtSm1rRU9HcTNOV3ZZOVFxd08xNVVvRThxSnlrZ2NWb25RNlRtR1VBU0xIS3FBOGpldDg1a1lOQUg5NmxwQm02X1pCUlBYanFUY2pSQjBWa0lIVktQcE9tdklOc2ZRVWJLNlZWX3kteEJ2LW44TXVGRWk5MDNIRVBmRkFpUkRWbkRDRWJRVmxFYkdJVnh5VHpPbmxJQlBXY0ZvcnByOUo3YlV0S2l3MUVZTEVwQ0lDcVBQeW92S2UyZDQ2ZVRtZVJTbG5EV3dqdW1Zb2Z4azVlNXZxYWpIcFJrTXJaVG9RRjBZV2VOeVp3RHkyYjNsSFc0RG1PT01nM2E4VG1sQXp0LXZhYmZVSjJ1OWE?oc=5" target="_blank">Outcomes in Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Curative-Intent Treatment</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL
AJMCgeneral

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPbFRLUkk2dm9TSTMzR3FCbWEyU3VjbE1SQXhvUWZ2S0VfY1REMUJ5cUFFU091M2ZqZnEyb2htQlhpNXJDTGRWOThBazMtYW1vOUJzbDU5bUxHX2JnQlVMb28tUk1rUHl4VWZDRWduU3ZVTmdJbU9GeUdmZi1sTHJHVGZIR3NHNlFlTTdaSThYZzhYbzdfenZpS3dmRTlXb2ZiT3FVaDFR?oc=5" target="_blank">Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
Haematologicageneral

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBEVnlrMmhwOVpsS3R5S1ZpMkc4dnVxQkRNUmV6ZXZIS296ZlRpSkthR2FWSGFKMEV3RERKQklTa1pVbVVYUDRJZTc1a0lSdFpIUm5DUWdZMA?oc=5" target="_blank">Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin</a>  <font color="#6f6f6f">Haematologica</font>

Read Full StoryMore like this
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland | Bone Marrow Transplantation
Naturegeneral

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland | Bone Marrow Transplantation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1qeFBISnEyNWx3dUQxdjRLNm43ZlNpTzhXcjV3b3h0VjZEcHNVenBIQkMzSFlBV2JWZXlTZlNpTDhLZU9qTFI1N2twdnBOOTFhaFRnYVBFQlZCNVBmNmQw?oc=5" target="_blank">Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland | Bone Marrow Transplantation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
Naturegeneral

Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5tZ1Z0UFRURXBfVVlyV2dWRnlwNE00anB0U05nRmQxb25aSUpLN1dmNTFlcHFnbE9mQU5YbDBWX29jMEoyZWtyM0xIMklDUjBOTDVXTHAtMUg0Y3JqeWlR?oc=5" target="_blank">Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Blinatumomab improves outcomes in relapsed pediatric leukemia
National Cancer Institute (.gov)general

Blinatumomab improves outcomes in relapsed pediatric leukemia

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQeXNRalV0VTBqNmVEQnNEZ1FmQUlwUDNpeVBWRjVrZWFYUXhCTklBWG1PcElTWHljVVpUTHdKVjNjVHZBVU9FYmg2WnFKZ04yLXBwenRQYjFUN29BZUNWQWNBR2M5S0dlck9VTU4wWDRPOVNnTlRuY2xQNFU1Ty1HTkd6MGFGbnM?oc=5" target="_blank">Blinatumomab improves outcomes in relapsed pediatric leukemia</a>  <font color="#6f6f6f">National Cancer Institute (.gov)</font>

Read Full StoryMore like this
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Haematologicageneral

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE16aEMtc3JSakp6bXFZeEdrVE1EQ3hTVXd5NklNUFc2NGNvWXYxa1pSTFpYZ0RlaTlSVEN5RjdnSTlscnBaVWZMQmt0SUVoV0xmeTRiOHNR?oc=5" target="_blank">International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia</a>  <font color="#6f6f6f">Haematologica</font>

Read Full StoryMore like this
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database | British Journal of Cancer
Naturegeneral

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database | British Journal of Cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE91cGladmFYVjFVMm9IS0l6R2ZOMmMxUFVPcWxRSXo1SXhfei1CT1NYaEFPMDNsMU1aeTl0UVZfeDdBYjdGeGlvN3JzV01sWWxJVlZ4QXFGZ0tpbGhNWTdn?oc=5" target="_blank">Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database | British Journal of Cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Long-term outcomes following CAR T cell therapy: what we know so far
Naturegeneral

Long-term outcomes following CAR T cell therapy: what we know so far

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1aRWlzV25laDFJakx2TGhTWEoyUjQ5NlJlamsxU3Z6NHVkTlVFV0dDaHRwRk5TTnNlNzltTkNENGU3M2ZiOFVUR2haSVE3ME1nT0dwOVU4QmNaWEJyd204?oc=5" target="_blank">Long-term outcomes following CAR T cell therapy: what we know so far</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
The ASCO Postgeneral

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMXg2Um4weDRlT0xvamJUR2xQVHczTWpzay1Ec0VkR0ROcnljakNyeVNJbkMySEJxN3pqUmNqOVNoY1A5M2N4TWlKSDhBMnJaLUxyTU5ESUEyQ0dCWnZrYzRaR19mS3dOSVlndk15SXRtYVJIWGIyRUtrSlRlWXNjQzZFLVFSNDJaaElRajNHckhpaGdJNUxqLW9CT29CbThialFHSmpobnRiQm95dHd4Z3d6R0JtZWlIaktCWFhQbFR3OEZJM1k4S1gzN2lwSnAyMUEwTGF0ZktvZGRSZUszWldfcDFxekF6cFRybGVTSjRhZw?oc=5" target="_blank">Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Outcomes in children with first‐relapsed acute lymphoblastic leukemia in Japan: Results from JCCG Study JPLSG‐ALL‐R08 - Yamanaka - 2024 - Pediatric Blood & Cancer
Wiley Online Librarygeneral

Outcomes in children with first‐relapsed acute lymphoblastic leukemia in Japan: Results from JCCG Study JPLSG‐ALL‐R08 - Yamanaka - 2024 - Pediatric Blood & Cancer

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE5fMXBQX2hYZlU3TFRFZ2JpYjJkY0liMHc3SFBmeklLUW1oNWs0TzVCd2MwZnRLV3dGZDE3VUVsZmNvMVo0NlEzNWZtMXV6OFBwSV9zUVBzZnJoUWZXZDVBbDBDSnhKWl9iQXc?oc=5" target="_blank">Outcomes in children with first‐relapsed acute lymphoblastic leukemia in Japan: Results from JCCG Study JPLSG‐ALL‐R08 - Yamanaka - 2024 - Pediatric Blood & Cancer</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis | Leukemia
Naturegeneral

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis | Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1hMmxHc2JxRjNDSGRNdlY3Sms1MXBTTmJveWk0RmpuRmRKcDRZdEZRZUgxaUhjcUVqTUI5NEpSeGJiUXRqYjNoTUpmaUJId3B4ZDVRN1d1c2dhaHV3Z1pN?oc=5" target="_blank">Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis | Leukemia</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
Naturegeneral

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFAtdUxBSEl2bDBWTFpYdEVyVlJXQTZQU1FDV2FnZHFvT0h2X2Z6SDNfajh2cXRRRlo4WEdpdThHQ1Rvdmtwb2E1emMtY1VTRW10WjZFODFSbnVRa1k3eTJN?oc=5" target="_blank">Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T
Targeted Oncologygeneral

Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPNGFUU0RNbjc5UV9mdThjc05GMjlERW9tcDluMjV0Q0Q2Vlc2U3hSRDJMbE9LYnBMRjdnZnBpWVlhajJETjMwX3prYmxyd3d3MlRFRlNCc3ZBVGFQMHg5UDVFVnMwejBXVUZOdVVLOHdLcmFwemdIVmRKTnRidFJSV25QMVBvX0hiVzJjYS1iU3l5OG9FUEhtVWZIUjFzVkcwOFE?oc=5" target="_blank">Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months
Wiley Online Librarygeneral

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE51SXhFSG1VTVF0SE1fbXNmWEMxXzZZSUl0c0x4dDVULVNfb0FRN3Rra3RWcjZxcmVmSnZUSTdhOEhhRkFkeVh0VTR4MjZqUnZJMVFBSkVUb2NHU3FEWmRwNF9jQkpwQ1RTY3c?oc=5" target="_blank">Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
"Outcomes of relapse after" — Live Google News Trends & Headlines